Business Wire

TINUBU-SQUARE

21.1.2021 13:02:12 CET | Business Wire | Press release

Share
Tinubu® Square Announces Technological Collaboration With Microsoft

Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces cooperation with Microsoft, the leading provider in Business Intelligence solutions.

Olivier Placca , Tinubu Square co-founder and Deputy CEO declares: “This cooperation is strategic for Tinubu Square to continue to offer carriers best-in-class technologies in the long run using the strength of Power BI across all business lines of our SaaS-based, end-to-end Enterprise Solution Platform. Our primary objective is answering our customers’ needs. Integrating Power BI to our Credit Insurance and Surety Platform offers them key benefits such as powerful insights, a scalable solution and settings on-the-fly. To take full advantage of our Business Intelligence capabilities, customers can tailor their own reports using a specifically designed Tinubu® CIS data model, increasing efficiency and data relevance.

Offer Sadey , Chief Technical Officer at Tinubu Square, explains: “Before choosing Microsoft, we ran through a market research with full technical assessment of the different offerings. We wanted to be sure to integrate the best solution for our customers’ benefit. It had to perfectly fit our own solutions and enhance them; we found that Microsoft Power BI was the right technology for achieving that end.

Today, Power BI is integrated in both our Trade Credit Insurance and our Surety SaaS Solutions (Tinubu® CIS & Tinubu® eSURETY®). Choosing Power BI brings the assurance of benefiting from the best technical tool. It is scalable to the customer’s business needs and is highly secured. It has a strong API enabling carriers to personalize the whole configuration of the reports they need and customize their different workspaces. Configuration is actually very easy and can be done on-the-go. Customers can also connect to the Data Warehouse for their own needs of data analysis and prediction.

Another advantage is the cost; Power BI is very affordable and allows us to continue offering high-end technological services while remaining cost-competitive.

Overall, this collaboration with Microsoft is built on a solid policy: a progressive licensing mode and a strong global support – technical, legal and business - allowing rapid scalability and therefore growth for our customers.”

Patrice Amann , Senior Director, Financial Services Business Lead - EMEA, at Microsoft expresses: “Being at the vanguard of technological innovations, Microsoft developed Power BI which is specifically designed to facilitate businesses’ strategic decisions and growth.
Today, business forecasts and decision-making processes rely solely on the quality of data, transformed into knowledge, and their real-time availability. Every company is looking for the guaranty that their data and cloud services will be fully secured and supported at all time, whether their activities spread on a global scale or is purely local.”

He adds: “This collaboration with Tinubu Square shows that Microsoft Business Intelligence solutions are also designed to perfectly adjust to and match the need for digitalization in the Credit Insurance and Surety industry. Our goal is to provide the necessary technology to contribute to the large success of Tinubu Square’s specialized solutions for carriers, and this cooperation materializes a joint intention between both companies to answer exact business needs and provide an always optimized customer experience.”

About Tinubu Square www.tinubu.com@TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.

Link:

ClickThru

Social Media:

https://www.facebook.com/tinubu.square.35

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye